More Company News

Futura Medical

Pricing of $110m public offering of ADSs
23 Jan 2020Read More

Futura Medical

Proposed public offering of ADSs
22 Jan 2020Read More

Futura Medical

Result of general meeting
20 Jan 2020Read More

Futura Medical

Third agreement signed for antibody platform
20 Jan 2020Read More

Futura Medical

Surufatinib Phase III SANET-p study meets primary endpoint at interim analysis and will stop early
20 Jan 2020Read More

Futura Medical

FY19 trading update
20 Jan 2020Read More

Futura Medical

Technology licencing discussions ended with leading California-based academic institution
16 Jan 2020Read More

Futura Medical

Additional positive data from Phase 2b ASTEROID study
14 Jan 2020Read More

Futura Medical

Mereo and Oncologie enter global licensing agreement for navicixizumab
13 Jan 2020Read More

Futura Medical

Initiation of Phase II trial of Surufatinib in combination with Tuoyi in patients with advanced solid tumours
13 Jan 2020Read More

1 2 3 4 … 32
Return to Futura Medical
© 2019 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).